PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Purchased by Jump Financial LLC

Jump Financial LLC lifted its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 318.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 49,865 shares of the company's stock after purchasing an additional 37,935 shares during the period. Jump Financial LLC owned about 0.10% of PROCEPT BioRobotics worth $4,015,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of PRCT. Raleigh Capital Management Inc. acquired a new stake in PROCEPT BioRobotics in the fourth quarter worth about $32,000. Signaturefd LLC increased its stake in PROCEPT BioRobotics by 26.7% during the 4th quarter. Signaturefd LLC now owns 689 shares of the company's stock valued at $55,000 after purchasing an additional 145 shares in the last quarter. IFP Advisors Inc purchased a new position in shares of PROCEPT BioRobotics in the fourth quarter worth $58,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of PROCEPT BioRobotics during the third quarter valued at $64,000. Finally, Arcadia Investment Management Corp MI acquired a new position in shares of PROCEPT BioRobotics in the fourth quarter valued at about $64,000. Hedge funds and other institutional investors own 89.46% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Morgan Stanley cut their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Truist Financial reduced their price objective on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, April 11th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $91.43.

PROCEPT BioRobotics Price Performance

NASDAQ PRCT traded down $0.87 during mid-day trading on Tuesday, hitting $52.57. The stock had a trading volume of 153,256 shares, compared to its average volume of 783,774. PROCEPT BioRobotics Co. has a twelve month low of $47.04 and a twelve month high of $103.81. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The firm's 50 day moving average is $58.90 and its 200 day moving average is $74.53. The stock has a market capitalization of $2.88 billion, a price-to-earnings ratio of -27.05 and a beta of 1.09.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million. Equities research analysts forecast that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Insider Transactions at PROCEPT BioRobotics

In related news, CFO Kevin Waters sold 733 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $41,824.98. Following the transaction, the chief financial officer now owns 107,991 shares of the company's stock, valued at approximately $6,161,966.46. This represents a 0.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the transaction, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at approximately $9,875,374.20. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,455 shares of company stock worth $368,322 in the last 90 days. Insiders own 17.40% of the company's stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).